The Ontario Bioscience Innovation Organization (OBIO) is proud to announce its 2021 Capital Access Advisory Program (CAAP) and the high-potential health science companies in this year’s cohort. CAAP 2021 logos.
Hamilton-based ToeFx and Eye3 are set to join 6 other companies that make up the 2021 CAAP cohort.
Now in its ninth year, OBIO CAAP companies will work with OBIO and a vast network of expert advisors over the next year to achieve key goals and objectives that will position them for successful financing. OBIO CAAP operates downstream from existing entrepreneurship programs and focuses on accelerating technology commercialization, post-seed financing and strategic partnerships. OBIO CAAP creates high-value deal flow for both companies and investors, culminating with a presentation at the OBIO Investment Summit at which presenting companies have raised over $700M since 2018.
Read the OBIO press release here